
- 304 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
About this book
This book is the most comprehensive and complete treatise on nucleic acid therapeutic
products, including mRNA vaccines, their manufacturing, formulations, and
testing for safety and efficacy. Details include cGMP-compliant manufacturing and
regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented
to secure fast approval of copies of mRNA vaccines. Projections of financial plans
to establish RNA manufacturing facilities are provided, along with details of supply
chain management. Finally, the future of nucleic acid products in gene therapy and
other newer applications is presented, along with a perspective that all new vaccines
will be the nucleic acid type that will further provide first-time prevention of autoimmune
disorders. It is projected that both big pharma and start-ups will enter this field,
and we can expect significant additions to our drug armamentarium soon.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover
- Half-Title
- Title
- Copyright
- Dedication
- Contents
- Preface and Perspective
- Acknowledgments
- Author
- Background
- Chapter 1 The Genome Machine
- Chapter 2 Understanding Nucleic Acids
- Chapter 3 RNA Therapeutics
- Chapter 4 Nucleoside Vaccines
- Chapter 5 cGMP mRNA Vaccine Manufacturing
- Chapter 6 Regulatory Guidance
- Appendix 1: COVID-19 mRNA Vaccine Manufacturing Feasibility
- Appendix 2: Pharmacopeial Testing
- Appendix 3: Suggested Reading
- Index